Both in Biotechnology
Neumora Therapeutics vs Outlook Therapeutics
Over the past year NMRA returned −80.3% and OTLK returned −64.6%; their daily moves had a correlation of 0.17.
NMRA −80.3% OTLK −64.6%Growth of $1, one year, split-adjusted
| Metric | NMRA | OTLK |
|---|---|---|
| Price | $0.5932 | $0.4600 |
| Market cap | $111.5M | $112.0M |
| Today | +3.91% | 0.00% |
| 1 month | +25.9% | −19.6% |
| 6 months | −74.5% | +98.4% |
| Year to date | −66.9% | −70.9% |
| 1 year | −80.3% | −64.6% |
| Revenue growth (YoY) | — | −99.4% |
| Gross margin | — | −95.0% |
| Net margin | — | −233554.9% |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $63.9M | -$7.0M |
| Dividend yield | — | — |
| Volatility (60d) | 126.1% | 89.0% |
| Short % of float | 6.9% | 39.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).